MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

Albert L H J Aarnoudse; Ron H N van Schaik; Jeanne Dieleman; Mariam Molokhia; Melanie M van Riemsdijk; Robert J Ligthelm; David Overbosch; Ilse P van der Heiden; Bruno H Ch Stricker

doi:10.1016/j.clpt.2006.07.003

MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

Albert L H J Aarnoudse, Ron H N van Schaik, Jeanne Dieleman, Mariam Molokhia, Melanie M van Riemsdijk, Robert J Ligthelm, David Overbosch, Ilse P van der Heiden, Bruno H Ch Stricker

Population Health Sciences

Research output: Contribution to journal › Article › peer-review

70 Citations (Scopus)

Abstract

Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects. We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.

Original language	English
Pages (from-to)	367-74
Number of pages	8
Journal	Clinical Pharmacology and Therapeutics
Volume	80
Issue number	4
DOIs	https://doi.org/10.1016/j.clpt.2006.07.003
Publication status	Published - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clpt.2006.07.003

Cite this

@article{23268857f6194f9796d2a05c1b95d840,

title = "MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine",

abstract = "Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects. We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.",

author = "Aarnoudse, {Albert L H J} and {van Schaik}, {Ron H N} and Jeanne Dieleman and Mariam Molokhia and {van Riemsdijk}, {Melanie M} and Ligthelm, {Robert J} and David Overbosch and {van der Heiden}, {Ilse P} and Stricker, {Bruno H Ch}",

year = "2006",

doi = "10.1016/j.clpt.2006.07.003",

language = "English",

volume = "80",

pages = "367--74",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "WILEY-BLACKWELL",

number = "4",

}

TY - JOUR

T1 - MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

AU - Aarnoudse, Albert L H J

AU - van Schaik, Ron H N

AU - Dieleman, Jeanne

AU - Molokhia, Mariam

AU - van Riemsdijk, Melanie M

AU - Ligthelm, Robert J

AU - Overbosch, David

AU - van der Heiden, Ilse P

AU - Stricker, Bruno H Ch

PY - 2006

Y1 - 2006

N2 - Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects. We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.

AB - Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects. We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.

U2 - 10.1016/j.clpt.2006.07.003

DO - 10.1016/j.clpt.2006.07.003

M3 - Article

C2 - 17015054

SN - 0009-9236

VL - 80

SP - 367

EP - 374

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 4

ER -

MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this